19 completed, 6 unknown, 4 terminated. 29 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 29 | Completed 19, Unknown 6, Terminated 4 |
Follow Basiliximab: new trials by email Literature Review of Basiliximab trials Research Report on Basiliximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement Basiliximab, Vedolizumab - Safety and Efficacy | Phase 4 | Unknown | The First Affiliated Hospital of Soochow University | 45 | 2022-08-01 | 2023-10-04 |
| Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR Twice-daily Tacrolimus, Once-daily envarsus XR, Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG) - Kidney Transplantation, Kidney Transplant Rejection | Phase 4 | Terminated | University of Southern California | 20 | 2021-11-23 | 2025-11-10 |
| Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant Basiliximab 20 MG - Asses Immunosuppression Modulation on Renal Recovery Post LT | Phase 4 | Completed | Fady M Kaldas, M.D., F.A.C.S. | 71 | 2021-01-15 | 2025-12-16 |
| Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD Ruxolitinib - Safety and Efficacy | Phase 4 | Unknown | The First Affiliated Hospital of Soochow University | 50 | 2020-12-15 | 2021-08-25 |
| Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients Basiliximab 20 milligram [Simulect], Normal Saline - Kidney Transplantation | Phase 4 | Unknown | King Faisal Specialist Hospital & Research Center | 140 | 2020-09-01 | 2021-02-18 |
| Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome Mycophenolate mofetil 500mg Tab. or 250mg Cap., Tacrolimus, Methylprednisolone/prednisolone - Kidney Transplant | Phase 4 | Completed | Chong Kun Dang Pharmaceutical | 169 | 2018-03-31 | 2024-05-22 |
| Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation Antithymocyte Immunoglobulin (Rabbit), Interleukin 2 Receptor Antagonist - Kidney Transplant Rejection | Phase 4 | Unknown | University of Khartoum | 300 | 2018-03-21 | 2019-01-03 |
| Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Busulfan, Cyclophosphamide, Fludarabine - Thalassemia Major | Phase 4 | Unknown | First Affiliated Hospital of Guangxi Medical University | 30 | 2017-04-01 | 2017-05-31 |
| Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients Basiliximab, Thymoglobulin - Kidney Transplant Rejection, Kidney Transplant; Complications | Phase 4 | Completed | Coordinación de Investigación en Salud, Mexico | 100 | 2016-12-01 | 2019-11-15 |
| Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Basiliximab,, Tacrolimus, Methotrexate - Beta-Thalassemia Major, Graft-versus-host Disease (GVHD) | Phase 4 | Completed | Zhongming Zhang | 205 | 2015-04-01 | 2025-06-18 |
| Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients sirolimus, tacrolimus, mycophenolate - Disorder Related to Renal Transplantation, Cytomegalovirus Infections | Phase 4 | Completed | Associação Médico Espírita de Botucatu | 48 | 2014-01-01 | 2016-02-17 |
| Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) Induction therapy, Corticosteroids, EVR+rCNI - End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD) | Phase 4 | Completed | Novartis Pharmaceuticals | 2037 | 2013-12-03 | 2019-01-30 |
| Simulect Versus ATG in Sensitized Renal Transplant Patient Simulect, ATG Fresenius - Renal Transplant Rejection | Phase 4 | Completed | University Hospital, Toulouse | 60 | 2013-09-01 | 2026-04-08 |
| A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids Advagraf, Mycophenolate Mofetil, Simulect - Kidney Transplantation | Phase 4 | Completed | Astellas Pharma Inc | 1166 | 2011-01-22 | 2024-11-01 |
| Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment ATG-F, Simulect - Glomerulonephritis, IgAN | Phase 4 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 117 | 2011-01-08 | 2021-01-20 |
| Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation Basiliximab, Tacrolimus, Mycophenolic Acid - Liver Transplantation | Phase 4 | Completed | University of California, Los Angeles | 59 | 2011-01-01 | 2022-09-29 |
| Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation Tacrolimus with rapid steroid withdrawal, Tacrolimus with steroids minimization, CsA with steroid minimization - Diabetes Mellitus, Adult-Onset | Phase 4 | Terminated | Armando Torres Ramírez | 134 | 2010-02-01 | 2024-10-22 |
| Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients Everolimus, Tacrolimus (FK506), Basiliximab - Chronic Renal Failure | Phase 4 | Completed | Novartis Pharmaceuticals | 36 | 2009-12-01 | 2014-08-15 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program Basiliximab, Enteric Coated Mycophenolic Acid (MPA), RAD001 - Renal Transplantation | Phase 4 | Terminated | Novartis Pharmaceuticals | 207 | 2009-07-01 | 2014-06-06 |
| Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation cyclosporine, Everolimus - Renal Transplantation | Phase 4 | Unknown | University Hospital, Antwerp | 152 | 2008-10-01 | 2009-05-18 |
Showing 20 of 29. Sign in to see all of them.
Kidney Failure, Chronic (2) · Rejection, Psychology (2) · Renal Insufficiency (2) · beta-Thalassemia (2) · Cytomegalovirus Infections (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Glomerulonephritis (1) · Graft vs Host Disease (1) · Liver Cirrhosis (1) · Neoplasms (1) · Renal Insufficiency, Chronic (1)
Novartis Pharmaceuticals (5) · Astellas Pharma Inc (3) · Novartis (3) · The First Affiliated Hospital of Soochow University (2) · Armando Torres Ramírez (1) · Associação Médico Espírita de Botucatu (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Chong Kun Dang Pharmaceutical (1) · Coordinación de Investigación en Salud, Mexico (1) · Fady M Kaldas, M.D., F.A.C.S. (1) · First Affiliated Hospital of Guangxi Medical University (1) · King Faisal Specialist Hospital & Research Center (1) · Thomas Jefferson University (1) · University Hospital Freiburg (1) · University Hospital, Antwerp (1)
Switzerland (6) · United States (6) · France (5) · Germany (5) · Belgium (4) · China (4) · Norway (4) · Spain (4) · Sweden (4) · Czechia (3) · Italy (3) · Mexico (3) · Netherlands (3) · Poland (3) · Portugal (3)
Fady M Kaldas, MD (2) · Xuefeng He, doctor (2) · Armando Torres, PhD (1) · Carlo Gerardo B Ramirez, M.D. (1) · Chang-Kwan Oh, Ph.D (1) · Christian Hugo, Prof. Dr. (1) · Gustavo Martinez-Mier, MD (1) · Jean-Louis Bosmans, MD/PhD (1) · Nassim Kamar, MD PhD (1) · Oliver Thomusch, Prof. Dr. (1) · Santhi Voora, MD (1)
PMID 16273116, PMID 16699456, PMID 16737942, PMID 17093248, PMID 18322043, PMID 22471345, PMID 22850297, PMID 27547871, PMID 27871759, PMID 29149958, PMID 29752413, PMID 31029086, PMID 31152476, PMID 31536556, PMID 32633157, PMID 32775820, PMID 33277746, PMID 34216395, PMID 34620664, PMID 37253803, PMID 37391381, PMID 39382091
2008 (1), 2009 (1)